Assessing cost-effectiveness in the management of multiple sclerosis

ClinicoEconomics and Outcomes Research

Volumn 1, Issue 1, 2009, Pages 61-78

  Phillips, Ceri J ^a   Humphreys, Ioan ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

Cost effectiveness; Cost effectiveness analysis; Cost utility analysis; Disease management; Immunomodulatory drugs; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISABILITY; DISEASE COURSE; DISEASE DURATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; MULTIPLE SCLEROSIS; QUALITY ADJUSTED LIFE YEAR; RELAPSE; REVIEW;

EID: 77953418489     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/ceor.s4225     Document Type: Review

References (126)

1. Dean G. How many people in the world have multiple sclerosis? Neuroepidemiology. 1994;13:1-7.
2. Hauser SL. Multiple sclerosis and other demyelinating diseases. In: Isselbacher KJ, Braunwald E, Wilson JD, et al, eds. Harrisons's Principles of Internal Medicine. New York: McGraw-Hill, 1994.
3. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Medical progress: multiple sclerosis. N Eng J Med. 2000;343:938-952.
4. Fieschi C, Pozzilli C, Bastianello S, et al. Human recombinant interferon beta in the treatment of relapsing-remitting multiple sclerosis: preliminary observations. Multiple Sclerosis. 1995;1:S28-S31.
5. http://www.mssociety.org.uk/news-events/news/press-releases/atlas. html. Accessed June 2009.
6. http://www.nationalmssociety.org/Sourcebook-Epidemiology.asp. Accessed 25 March 2003.
7. Richards RG, Sampson FC, Beard SM, Tappenden P. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. [abstract]. Health Technol Assess. 2002;6:1-73.
8. Weinshenker B, Bass B, Rice GP, Noseworthy J, et al. The natural history of multiple sclerosis: a geographically-based study. I. Clinical course and disability. Brain. 1989;112:133-146.
9. Weinshenker B, Bass B, Rice GP, Noseworthy J, et al. The natural history of multiple sclerosis: a geographically-based study. II. Predictive value of the early clinical course. Brain. 1989;112:11419-11428.
10. Rieumont MJ, Deluca SA. Neuroimaging evaluation in multiple sclerosis. Am Fam Physician. 1993;48:273-276.
11. Hibberd PL. The use and misuse of statistics for epidemiological studies of multiple sclerosis. Ann Neurol. 1994;36:S218-S230.
12. Lyseng-Williamson KA, Plosker GL. Management of relapsingremitting multiple sclerosis: def ining the role of subcutaneous recombinant interferon-b-1a (Rebifâ). Dis Manage Health Outcomes. 2002;10:307-325.
13. Clegg A, Bryant J, Milne R. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review. Health Technol Assess. 2000; 4:i-iv 1-101.
14. Francis DA. The current therapy of multiple sclerosis. J Clin Pharm Ther. 1993;18:77-84.
15. Nuijten MJC, Hutton J. Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis. Value Health. 2002;5:44-54.
16. Goodkin DE. Interferon beta therapy for multiple sclerosis. Lancet. 1998;352:1486-1487.
17. Henriksson F, Fredrikson S, Masterman T, Jönsson B. Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur J Neurol. 2000;8:27-35.
18. O'Brien B. Multiple Sclerosis. London, UK: Off ice of Health Economics; 1987.
19. Holmes J, Madgwick T, Bates D. The cost of multiple sclerosis. Br J Med Econ. 1995;8:181-193.
20. Henriksson F, Jönsson B. The economic cost of multiple sclerosis in Sweden in 1994. Pharmacoeconomics. 1998;13:597-606.
21. Murphy N, Confavreux C, Has J, et al. Economic evaluation of multiple sclerosis in the UK, Germany and France. Pharmacoeconomics. 1998;13:607-622.
22. Whetten-Goldstein K, Sloan F, Goldstein L, Kulas E. A comprehensive assessment of the cost of multiple sclerosis in the United States. Multiple Sclerosis. 1998;4:419-425.
23. Kobelt G, Lindgren P, Smala A, et al. Costs and quality of life in multiple sclerosis. An observational study in Germany. HEPAC. 2001;2:60-68.
24. Kobelt G, Lindgren P, Parkin D, et al. Costs and quality of life in multiple sclerosis. A cross-sectional observational study in the United Kingdom. Stockholm: Stockholm School of Economics, EFI Research Report No. 398, 2000.
25. Asche CV, Ho E, Chan B, et al. Economic consequences of multiple sclerosis for Canadians. Acta Neurol Scand. 1997;95:268-274.
26. The Canadian Burden of Illness Study group. Burden of illness of multiple sclerosis: Part I - cost of illness. Can J Neurol Sci. 1998;25:23-30.
27. Amato MP, Battaglia MA, Caputo D, et al. The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. J Neurol. 2002;249:152-163.
28. Tissot E, Woronoff-Lemsi MC. Multiple sclerosis: cost of the illness. Rev Neurol (Paris). 2001;157:1169-1174.
29. Grudzinski AN, Hakim Z, Cox ER, Bootman JL. The economics of multiple sclerosis. Distribution of costs and relationship to disease severity. Pharmacoeconomics. 1999;15:229-240.
30. Midgard R, Riise T, Nyland H. Impairment, disability, and handicap in multiple sclerosis. A cross-sectional study in an incident cohort in More and Romsdal County, Norway. J Neurol. 1996;243:337-344.
31. Rieckmann P. Early multiple sclerosis therapy in the effects of public health economics. Med Klin. 2001;96(Suppl 1):17-21.
32. Miltenburger C, Kobelt G. Quality of life and cost of multiple sclerosis. Clin Neurol Neurosurg. 2002;104:272-275.
33. Pugliatti M, Rosati G, Carton H, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol. 2006;13:700-722.
34. Kobelt G, Berg J, Lindgren P. Costs and quality of life in multiple sclerosis in The Netherlands. Eur J Health Econ. 2006;7:55-64.
35. Kobelt G, Berg J, Lindgren P, Battaglia M, Lucioni C, Uccelli A. Costs and quality of life of multiple sclerosis in Italy. Eur J Health Econ. 2006;7:45-54.
36. McCrone P, Heslin M, Knapp M, Bull P, Thompson A. Multiple Sclerosis in the UK: service use, costs, quality of life and disability. Pharmacoeconomics. 2008;26:847-860.
37. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Germany. Eur J Health Econ. 2006;7:34-44.
38. Kobelt G, Berg J, Lindgren P, Gerfin A, Lutz J. Costs and quality of life of multiple sclerosis in Switzerland. Eur J Health Econ. 2006;7:86-95.
39. Rotstein Z, Hazan R, Barak Y, Achiron A. Perspectives in multiple sclerosis health care: special focus on the costs of multiple sclerosis. 2006;5:511-516.
40. Kobelt G, Berg J, Lindgren P, Kerrigan J, Russell N, Nixon, R. Costs and quality of life of multiple sclerosis in the United Kingdom. Eur J Health Econ. 2006;7:96-104.
41. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Spain. Eur J Health Econ. 2006;7:65-74.
42. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Austria. Eur J Health Econ. 2006;7:14-23.
43. Kobelt G, Berg J, Atherley D, Jönsson B. Costs and Quality of Life in Multiple Sclerosis A Cross-Sectional Study in the USA Stockholm School of Economics in its series Working Paper Series in Economics and Finance with number 594; 2004.
44. Kobelt G. Costs and quality of life for patients with multiple sclerosis in Belgium. Eur J Health Econ. 2006;7:24-33.
45. Kobelt G, Pugliatti M. Cost of multiple sclerosis in Europe. Eur J Neurol. 2005;Suppl 12:63-67.
46. Kobelt G, Berg J, Lindgren P, Fredrikson S, Jönsson B. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2006;77:918-926.
47. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology. 1983;33:1444-1452.
48. Murphy N, Confavreux C, Haas J, König N, Roullet E, et al. Quality of life in multiple sclerosis in France, Germany and the United Kingdom. J Neurol Neurosurg Psychiatry. 1998;65:460-466.
49. The Canadian Burden of Illness Study Group. Burden of illness of multiple sclerosis: Part II: Quality of Life. Can J Neurol Sci. 1998;25:31-38.
50. Schiaffino KM, Shawaryn MA, Blum D. Assessing the psychosocial impact of multiple sclerosis: Learning from research on rheumatoid arthritis. J Neuro Rehab. 1996;10:81-89.
51. Rudick RA, Miller D, Clough JD, Gragg LA, Farmer RG. Quality of life in multiple sclerosis. Arch Neurol. 1992;49:1237-1242.
52. Aronson KJ. Quality of life among persons with multiple sclerosis and their caregivers. Neurology. 1997;48:74-80.
53. White DM. Treating the family with multiple sclerosis. Phys Med Rehabil Clin N Am. 1998;9:675-687.
54. Gregory RJ, Disler P, Firth S. Caregivers of people with multiple sclerosis: A survey in New Zealand. Rehabil Nurs. 1996;21:31-37.
55. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the Economic Evaluation of Healthcare Programmes. Oxford: Oxford University Press; 1997.
56. Stevenson VL, Thompson AJ. The management of multiple sclerosis: current and future therapies. Drugs today. 1998;34:267-282.
57. Freeman J, Johnson J, Rollinson S, Thompson A, Hatch J. Standards of health care for people with MS. Multiple Sclerosis Society; September 1997.
58. Nalone M, Lomaestro B. Outcomes assessment of drug treatment in multiple sclerosis trials. Pharmacoeconomics. 1996;9:198-210.
59. Milo R, Panitch H. Glatiramer acetate or interferon-b for multiple sclerosis? A guide to drug choice. CNS Drugs. 1999;11:289-306.
60. The IFBN Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: Final outcome of the randomized controlled trial. Neurology. 1995;45:1277-1285.
61. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, et al; Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: the Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39:285-294.
62. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing remitting multiple sclerosis. Lancet. 1998;352:1498-1504.
63. European Study Group on Interferon beta-1b in Secondary Progressive Multiple Sclerosis. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet. 1998;352:1491-1497.
64. The IFBN Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapse-remitting multiple sclerosis, I: Clinical results of a multicenter, randomized, double blind, placebo controlled trial. Neurology. 1993;43:655-661.
65. The IFBN Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years. Neurology. 1996;47:889-894.
66. Panitch H, Goodin D, Francis G, et al. Benefits of high-dose, high frequency interferon beta-1a in relapse remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J Neurol Sci. 2005;239:67-74.
67. Schwid SR, Thorpe J, Sharief M, et al. Enhanced benefit of increasing beta-1a dose and frequency in relapse remitting multiple sclerosis: the EVIDENCE study. Arch Neurol. 2005;62:785-792.
68. Sandberg-Wollheim M, Bever C, Carter J, et al. Comparative tolerance of IFN beta-1a regimens in patients with relapse remitting multiple sclerosis. J Neurol. 2005;252:8-13.
69. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med. 2000;343:898-904.
70. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet. 1998;352:1491-1497.
71. Kappos L, Polman CH, Freedman MS, et al; for the BENEFIT Study Group. Treatment with interferon beta1-b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67:1242-1249.
72. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon beta1-a in relapsing MS. Neurology. 2001;56:1628-1636. [erratum Neurology. 2001;57:1146].
73. Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis. Neurology. 2002;58:168-178.
74. Forbes RB, Lees A, Waugh N, Swingler RJ. Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis. BMJ. 1999;319:1529-1533.
75. van Oosten BW, Truyen L, Barkhof F, Polman CH. Choosing drug therapy for multiple sclerosis: an update. Drugs. 1998;56:555-569.
76. Mäurer M, Rieckmann P. Relapsing-remitting multiple sclerosis: what is the potential for combination therapy? BioDrugs. 2000;13:149-158.
77. Rice GPA. Tretment of secondary progressive multiple sclerosis: current recommendations and future prospects. BioDrugs. 1999;12:267-277.
78. Weinstock-Guttman, Jacobs LD. What is new in the treatment of multiple sclerosis? Drugs. 2000;59:401-410.
79. Fillippini G, Munari L, Incorvaia B, et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet. 2003;361:545-552.
80. Amato MP. Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents. Expert Opin Pharmacother. 2004;5:2115-2126.
81. lachenecker P, Rieckmann P. Health outcomes in multiple sclerosis. Curr Opin Neurol. 2004;17:257-261.
82. Holmoy Trygve, Celius, Elisabeth Gulowsen. Cost effectiveness of natalizumab in multiple sclerosis. Exp Rev Pharmacoeconom Outcomes Res. 2008;1:11-21.
83. Kobelt G. Health economic issues in MS. Int MS J. 2006;13:17-26.
84. Clegg A, Bryant J. Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness. Expert Opin Pharmacother. 2001;2:623-639.
85. Bryant J, Clegg A, Milne R. Systematic review of immunumodulatory drugs for the treatment of people with multiple sclerosis: is there good quality evidence on effectiveness and cost? J Neurol Neurosurg Psychiatry. 2001;70:574-579.
86. Teitelbaum D, Meshorer A, Hirshfiled T, et al. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol. 1971;1:242-248.
87. Simpson D, Noble S, Perry C. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis. CNS Drugs. 2002;16:825-850.
88. Johnson KP, Brooks BR, Ford CC, et a; Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years: Copolymer 1 Multiple Sclerosis Study group. Mult Scler. 2000;6:255-266.
89. Mikol DD, Barkhof F, Chang P, et al; REGARD study group. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the Rebif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008;7:903-914.
90. http://www.mssociety.org.uk/research/index.html.
91. Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002;360:2018-2025.
92. Gani R, Giovannoni G, Bates D, et al. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Pharmacoeconomics. 2008;26:617-627.
93. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899-910.
94. Kobelt G, Berg J, Lindgren P, et al. Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden. Mult Scler. 2008;14:679-690.
95. http://www.nice.org.uk/nicemedia/pdf/word/TA127Niceguidanceword. doc. Accessed May 2009.
96. Guo S, Bozkaya D, Ward A, et al. Treating relapsing multiple sclerosis with subcutaneous versus intramuscular interferon-beta-1a: modelling the clinical and economic implications. Pharmacoeconomics. 2009;27:39-53.
97. Brown MG, Murray TJ, Sketris IS, et al. Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression. First estimates. Int J Technol Assess Health Care. 2000;16:751-767.
98. Chilcott J, McCabe C, Tappenden P, et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. BMJ. 2003;326:522.
99. Kobelt G, Jönsson L, Fredrikson S. Cost-utility of interferon β1b 1-b in the treatment of patients with active relapsing-remiting or secondary progressive multiple sclerosis. Eur J Health Econom. 2003;4:50-59.
100. Parkin D, McNamee P, Jacoby A, Miller P, Thomas S, Bates D. A cost-utility analysis of interferon beta for multiple sclerosis. Health Technol Assess. 1998;2(4):iii-54.
101. Parkin D, Jacoby A, McNamee P, Miller P, Thomas S, Bates DA. Treatment of multiple sclerosis with interferon b: an appraisal of cost-effectiveness and quality of life. J Neurol Neurosurg Psychiatry. 2000;68:144-149.
102. Phillips CJ, Gilmour L, Gale R, Palmer M. A cost utility model of beta-interferon in the treatment of relapsing-remitting multiple sclerosis. J Med Econ. 2001;4:35-50.
103. Prosser LA, Kuntz KM, et al. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health. 2004;7:554-568.
104. Detournay B. The value of economic modelling studies in the evaluation of treatment strategies for multiple sclerosis. Value in Health. 2002;5:1-2.
105. Phillips CJ. The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment. CNS Drugs. 2004;18:561-574.
106. Kendrick M, Johnson KI. Long term treatment of multiple sclerosis with interferon beta may be cost-effective. Pharmacoeconomics. 2001;18:45-53.
107. McNamee P, Parkin D. Cost-effectiveness of interferon beta for multiple sclerosis: the implications of new information on clinical effectiveness. Health Technol Assess. 1999;2(4):169-179.
108. Iskedjian M, Walker JH, et al. Economic evaluation of Avonex (interferon beta-Ia) in patients following a single demyelinating event. Mult Scler. 2005;11:542-551.
109. Grima DT, Torrence GW, Francis G, Rice GP, Rosner AJ, Lafortune L. Cost and health related quality of life consequences of multiple sclerosis. Mult Scler. 2000;6:97-98.
110. Kobelt G, Jönsson L, Henriksson F, et al. Cost-utility of interferon beta 1b in secondary progressive multiple sclerosis. Int J Technol Assess Health Care. 2000;16:768-780.
111. Kobelt G, Jönsson L, Miltenberger C. Cost-utility of interferon beta 1b in secondary progressive multiple sclerosis, using natural history disease data. Int J Technol Assess Health Care. 2002;18:127-138.
112. Lazzaro C, Bianchi C, Peracino L, et al. Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon beta-1b. Neurol Sci. 2009;30:21-31.
113. Lepen C, Coyle P, Vollmer T, et al. Long-term cost effectiveness of interferon-beta-1a in the treatment of relapsing-remitting multiple sclerosis: an econometric model. Clin Drug Investig. 2003;23:571-581.
114. Bose U, Ladkani D, Burrell A, Sharief M. Cost-effectiveness analysis of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. J Med Econ. 2001;4:207-219.
115. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology. 1998;50:701-708.
116. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2006;77:918-926.
117. Berg J, Lindgren P, Fredrikson S, Kobelt G. Costs and quality of life of multiple sclerosis in Sweden. Eur J Health Econ. 2006;7:S75-S85.
118. Bell C, Graham J, Earnshaw S, et al. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm. 2007;13:245-261.
119. Touchette DR, Durgin TL, et al. A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis. Clin Ther. 2003;25:611-634.
120. Stolp-Smith KA, Atkinson EJ, Campion ME, et al. Health care utilization in multiple sclerosis: A population-based study in Olmstead County, MN. Neurology. 1998;50:1594-1600.
121. Stevens A, Colin-Jones D, Gabbay J. Quick and Clean: authoritative health technology assessment for local health care contracting. Health Trends. 1995;27:37-42.
122. Donaldson C, Mugford M, Vale L. Using systematic reviews in economic evaluation: the basic principles. In: Donaldson C, Mugford M, Vale L, eds. Evidence-Based Health Economics: From Effectiveness to Efficiency in Systematic Review. London: BMJ Books; 2002.
123. Towse A, Pritchard C. Does NICE have a threshold? An external view. In: Towse A, Pritchard C, Devlin N, eds. Cost-effectiveness Thresholds: Economic and Ethical Issues. London: Office of Health Economics; 2003.
124. Department of Health. Cost-effective provision of disease modifying therapies for people with multiple sclerosis. Health Service Circular 2002/004, February 2002. http://www.info.doh. gov.uk/doh/coin4.nsf/ 12d101b4f7b73d020025693c005488a9/ f4b139af5a7d8c2400256b52002e46e8/$FILE/ 004hsc2002.PDF
125. Fearon WF, Yeung AC, Lee DP, et al. Cost-effectiveness of measuring fractional flow reserve to guide coronary interventions. Am Heart J. 2003;145:882-887.
126. O'Brien BJ, Gertsen K, Willan AR, Faulkner LA. Is there a kink in consumers' threshold value for cost-effectiveness in health care? Health Econ. 2002;11:175-180.